AstraZeneca to strengthen cooperation with China

AstraZeneca's decision to invest more than 100 billion yuan ($14.39 billion) in China by 2030 marks a new chapter for the British drug-maker in a market it increasingly sees as central to global pharmaceutical innovation, said its chief executive officer, as China and the United Kingdom move to deepen economic and scientific cooperation.